Search results
Results from the WOW.Com Content Network
The Women's Interagency HIV Study (WIHS) was established in August 1993 to investigate the impact and progression of HIV disease in women. The WIHS enrolls both HIV-positive and HIV-negative women. The core portion of the study includes a detailed and structured interview, physical and gynecologic examination, and laboratory testing.
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
The CDC expanded the definition of HIV to include symptoms experienced by people of color and women in HIV trials and treatment recurrent pneumonia, pulmonary tuberculosis, stage III cervical cancer and recurrent vaginal candidiasis (yeast infections) [21] [34] The International Community of Women Living with HIV/AIDS (ICW) was founded. [11] 1993
There are variations in the health community in recommendations on what treatment doctors should recommend for people with HIV. One question, for example, is determining when a doctor should recommend that a patient take antiretroviral drugs and what drugs a doctor may recommend. This field also includes the development of antiretroviral drugs.
Although HIV PrEP medications are only available in oral tablet and injectable formulations, other formulations are being developed and studied. The emerging treatments expand HIV prevention strategies for women. For example, a vaginal gel formulation of tenofovir and an intravaginal ring releasing dapivirine are under investigation for ...
The human immunodeficiency virus (HIV) [8] [9] [10] is a retrovirus [11] that attacks the immune system.It is a preventable disease. [5] There is no vaccine or cure for HIV. It can be managed with treatment and become a manageable chronic health condition. [5]
In July 2017, The Lancet released an article revealing the results of a study conducted involving an injectable HIV-1 treatment to serve as a future replacement for the three-drug oral combination therapy. This new treatment would consist of two drugs: cabotegravir and rilpivirine, and injections would occur every four to eight weeks for each ...
The body uses its immune system to protect itself from bacteria, viruses and other disease-causing beings, and when it fails to do so immunodeficiency diseases occur. One such disease is acquired immunodeficiency syndrome which is most commonly a result of an infection by the human immunodeficiency virus (HIV). [1]